JP2020002172A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020002172A5 JP2020002172A5 JP2019167098A JP2019167098A JP2020002172A5 JP 2020002172 A5 JP2020002172 A5 JP 2020002172A5 JP 2019167098 A JP2019167098 A JP 2019167098A JP 2019167098 A JP2019167098 A JP 2019167098A JP 2020002172 A5 JP2020002172 A5 JP 2020002172A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- monoclonal antibody
- seq
- administered
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562232343P | 2015-09-24 | 2015-09-24 | |
| US62/232,343 | 2015-09-24 | ||
| US201662375825P | 2016-08-16 | 2016-08-16 | |
| US62/375,825 | 2016-08-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515658A Division JP2018532728A (ja) | 2015-09-24 | 2016-09-23 | （持続性）外傷後頭痛の予防、治療および低減 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020002172A JP2020002172A (ja) | 2020-01-09 |
| JP2020002172A5 true JP2020002172A5 (enExample) | 2020-09-10 |
Family
ID=57121460
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515658A Pending JP2018532728A (ja) | 2015-09-24 | 2016-09-23 | （持続性）外傷後頭痛の予防、治療および低減 |
| JP2019167098A Pending JP2020002172A (ja) | 2015-09-24 | 2019-09-13 | （持続性）外傷後頭痛の予防、治療および低減 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515658A Pending JP2018532728A (ja) | 2015-09-24 | 2016-09-23 | （持続性）外傷後頭痛の予防、治療および低減 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20170088612A1 (enExample) |
| EP (1) | EP3353202B1 (enExample) |
| JP (2) | JP2018532728A (enExample) |
| KR (2) | KR20180058777A (enExample) |
| CN (1) | CN108473560A (enExample) |
| AU (2) | AU2016325738A1 (enExample) |
| CA (1) | CA2999809A1 (enExample) |
| EA (1) | EA201890578A1 (enExample) |
| ES (1) | ES2846878T3 (enExample) |
| HK (1) | HK1258385A1 (enExample) |
| IL (1) | IL258008A (enExample) |
| MX (1) | MX2018003713A (enExample) |
| WO (1) | WO2017051385A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108014334B (zh) | 2011-05-20 | 2021-11-30 | H.伦德贝克公司 | 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途 |
| PT3495392T (pt) | 2011-05-20 | 2021-09-22 | H Lundbeck As | Composições anti-cgrp e a sua utilização |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| US10117836B2 (en) | 2014-02-05 | 2018-11-06 | Merck Sharp & Dohme Corp. | Tablet formulation for CGRP active compounds |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| MX378344B (es) | 2014-03-21 | 2025-03-10 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos. |
| SMT202600087T1 (it) | 2016-09-23 | 2026-03-09 | Teva Pharmaceuticals Int Gmbh | Trattamento dell’emicrania refrattaria |
| US12398209B2 (en) * | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US10899826B1 (en) | 2018-09-13 | 2021-01-26 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for an anti-CGRP antagonist antibody |
| CR20210373A (es) | 2019-01-08 | 2021-08-19 | H Lundbeck As | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp |
| US20200383983A1 (en) * | 2019-04-18 | 2020-12-10 | Allergan Sales, Llc | Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo |
| GEAP202515803A (en) | 2019-05-02 | 2025-06-10 | H Lundbeck As | Treatment of headache using anti-cgrp antibodies |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
| CA3181130A1 (en) | 2020-06-03 | 2021-12-09 | William J. Binder | Zonal and targeted methods and uses for treating a migraine disorder |
| MX2023001071A (es) | 2020-07-29 | 2023-05-12 | Allergan Pharmaceuticals Int Ltd | Tratamiento de la migraña. |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| JP2024533756A (ja) | 2021-09-27 | 2024-09-12 | アラガン ファーマスーティカルズ インターナショナル リミテッド | アトゲパントを含む片頭痛の併用療法 |
| WO2026149405A1 (zh) * | 2025-01-10 | 2026-07-16 | 齐鲁制药有限公司 | 一种抗人cgrp抗体的药物组合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9704770D0 (sv) * | 1997-12-19 | 1997-12-19 | Astra Ab | New use |
| SI3045182T1 (en) * | 2005-11-14 | 2018-08-31 | Teva Pharmaceuticals International Gmbh | An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates |
| PT3495392T (pt) * | 2011-05-20 | 2021-09-22 | H Lundbeck As | Composições anti-cgrp e a sua utilização |
| EP2802659A1 (en) * | 2012-01-10 | 2014-11-19 | Noxxon Pharma AG | Nucleic acids specifically binding cgrp |
| US8722060B2 (en) * | 2012-05-23 | 2014-05-13 | William J. Binder | Method of treating vertigo |
-
2016
- 2016-09-23 JP JP2018515658A patent/JP2018532728A/ja active Pending
- 2016-09-23 CA CA2999809A patent/CA2999809A1/en not_active Abandoned
- 2016-09-23 KR KR1020187011355A patent/KR20180058777A/ko not_active Ceased
- 2016-09-23 EA EA201890578A patent/EA201890578A1/ru unknown
- 2016-09-23 WO PCT/IB2016/055720 patent/WO2017051385A1/en not_active Ceased
- 2016-09-23 HK HK19100783.0A patent/HK1258385A1/zh unknown
- 2016-09-23 KR KR1020207008057A patent/KR20200035163A/ko not_active Withdrawn
- 2016-09-23 MX MX2018003713A patent/MX2018003713A/es unknown
- 2016-09-23 EP EP16778888.4A patent/EP3353202B1/en active Active
- 2016-09-23 AU AU2016325738A patent/AU2016325738A1/en not_active Abandoned
- 2016-09-23 US US15/274,331 patent/US20170088612A1/en not_active Abandoned
- 2016-09-23 ES ES16778888T patent/ES2846878T3/es active Active
- 2016-09-23 CN CN201680068514.8A patent/CN108473560A/zh active Pending
-
2018
- 2018-03-11 IL IL258008A patent/IL258008A/en unknown
-
2019
- 2019-06-11 US US16/437,776 patent/US20200148761A1/en not_active Abandoned
- 2019-09-13 JP JP2019167098A patent/JP2020002172A/ja active Pending
- 2019-11-06 AU AU2019261726A patent/AU2019261726A1/en not_active Abandoned
-
2021
- 2021-04-05 US US17/222,737 patent/US20220048986A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019530683A5 (enExample) | ||
| JP2008540447A5 (enExample) | ||
| JP2020503260A5 (enExample) | ||
| EP3201231B1 (en) | Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28 | |
| JP2014114288A5 (enExample) | ||
| JP2017510579A5 (enExample) | ||
| JP2023524149A5 (enExample) | ||
| TW201024315A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide | |
| KR20120100914A (ko) | 에프라투주맙을 이용한 자가면역 및 염증 질환의 치료 | |
| RU2019140933A (ru) | Средства, пути применения и способы лечения | |
| RU2017145662A (ru) | Моноклональные антитела и способы их применения | |
| JP2022531408A5 (enExample) | ||
| JP2020527152A5 (enExample) | ||
| JP2018529635A5 (enExample) | ||
| RU2013157177A (ru) | Способы лечения системной красной волчанки, склеродермии и миозита | |
| JP2020515577A5 (enExample) | ||
| IL292706A (en) | Type i interferon inhibition in systemic lupus erythematosus | |
| JP2021502065A5 (enExample) | ||
| US20220213203A1 (en) | Dosing Regimens of Bispecific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies | |
| JP2025515092A5 (enExample) | ||
| JP2022500382A5 (enExample) | ||
| US20250263472A1 (en) | Compositions and methods for treating and suppressing allergic responses | |
| WO2023009434A1 (en) | Methods for treating acute myeloid leukemia with anti-ilt3 antibodies | |
| Rose et al. | Monoclonal antibody treatments for multiple sclerosis | |
| TW202508630A (zh) | 治療表現ｃｄ２０之ｂ細胞癌症之方法 |